2m 2m 2m 2m 2m 2m 2m
UROGEN PHARMA (URGN)
NASDAQ
$35.09+$0.09 (+0.27%)
Price as of Jun 23, 2026 3:18 PM EDT- $1.6BMarket Cap
- 144.69%1-Year Change
- BiotechnologyIndustry
UROGEN PHARMA (URGN)
$35.09+$0.09 (+0.27%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 109.8M +21.45% | 90.4M +9.29% | 82.7M +28.52% | 64.4M +33.96% | |
Cost of Revenue | 12.4M +40.15% | 8.9M -5.13% | 9.4M +22.30% | 7.7M +48.42% | |
Gross Profit | 97.3M +19.41% | 81.5M +11.13% | 73.4M +29.36% | 56.7M +32.22% | |
Sales and Marketing Expense | 155.1M +28.02% | 121.2M +29.89% | 93.3M +12.60% | 82.8M -5.37% | |
Research and Development Expense | -67.1M +17.43% | -57.1M +25.28% | -45.6M -13.78% | -52.9M +11.05% | |
Depreciation and Amortization Expense | 307,000 -6.69% | 329,000 -58.98% | 802,000 -13.20% | 924,000 +11.19% | |
Total Operating Expenses | 155.1M +28.02% | 121.2M +29.89% | 93.3M +12.60% | 82.8M -5.37% | |
Operating Profit | -124.9M +29.01% | -96.8M +47.68% | -65.5M -17.09% | -79.0M -14.36% | |
Interest Income | 6.0M -32.99% | 8.9M +237.03% | 2.6M +161.49% | 1.0M +176.71% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 6.0M -32.99% | 8.9M +237.03% | 2.6M +161.49% | 1.0M +176.71% | |
Total Nonoperating Income and Expense | -670,000 +192.58% | -229,000 -127.33% | 838,000 +1,063.89% | 72,000 N/A | |
Income before Taxes | -153.4M +23.68% | -124.0M +26.16% | -98.3M -8.98% | -108.0M -1.23% | |
Income Taxes | 78,000 -97.25% | 2.8M -27.76% | 3.9M +123.36% | 1.8M +21.12% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -153.5M +20.98% | -126.9M +24.09% | -102.2M -6.87% | -109.8M -0.94% | |
Net Income from Continuing Operations Applicable to Common | -153.4M +23.68% | -124.0M +26.16% | -98.3M -8.98% | -108.0M -1.23% | |
Basic EPS and Net Income | -3.19 +7.77% | -2.96 -16.62% | -3.55 -26.20% | -4.81 -3.02% | |
Diluted EPS and Net Income | -3.19 +7.77% | -2.96 -16.62% | -3.55 -26.20% | -4.81 -3.02% | |
Basic Weighted Average Shares | 48.1M +12.22% | 42.9M +48.70% | 28.8M +26.43% | 22.8M +2.06% | |
Diluted Weighted Average Shares | 48.1M +12.22% | 42.9M +48.70% | 28.8M +26.43% | 22.8M +2.06% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 110.7M -35.61% | 172.0M +81.04% | 95.0M +71.46% | 55.4M +24.91% | |
Short-Term Investments | 9.7M -84.99% | 64.7M +54.17% | 42.0M -5.81% | 44.6M -0.50% | |
Cash and Cash Equivalents and Short-Term Investments | 120.5M -49.11% | 236.7M +72.80% | 137.0M +37.02% | 100.0M +12.14% | |
Total Current Assets | 186.0M -32.63% | 276.1M +63.21% | 169.2M +31.25% | 128.9M +12.69% | |
Accumulated Depreciation | 4.6M +7.15% | 4.3M +8.32% | 4.0M +25.46% | 3.1M +41.51% | |
Property and Plant and Equipment and Net | 637,000 -2.75% | 655,000 -4.93% | 689,000 -46.88% | 1.3M -34.06% | |
Total Long-Term Assets | 5.2M +776.23% | 589,000 -71.10% | 2.0M -25.62% | 2.7M +109.00% | |
Total Assets | 200.5M -29.84% | 285.7M +60.23% | 178.3M +31.48% | 135.6M +13.26% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 46.4M +1.02% | 45.9M +47.22% | 31.2M +30.51% | 23.9M +6.86% | |
Total Long-Term Debt | 122.2M +0.39% | 121.7M +23.52% | 98.6M +1.04% | 97.5M N/A | |
Total Long-Term Liabilities | 122.2M +0.39% | 121.7M +22.47% | 99.4M +0.27% | 99.1M +24,805.28% | |
Total Liabilities | 305.9M +3.88% | 294.5M +20.94% | 243.5M +8.24% | 225.0M +102.08% | |
Retained Earnings | -959.7M +19.04% | -806.2M +18.68% | -679.3M +17.72% | -577.1M +23.49% | |
Total Stockholders Equity | -105.5M +1,098.16% | -8.8M -86.50% | -65.2M -27.02% | -89.4M -1,162.18% | |
Total Shares Outstanding | 48.4M +14.49% | 42.2M +29.98% | 32.5M +40.47% | 23.1M +2.97% | |
Cash Flow | |||||
Cash from Operating Activities | -162.4M +67.87% | -96.8M +26.70% | -76.4M -12.77% | -87.6M +3.14% | |
Capital Expenditures | 289,000 -2.03% | 295,000 +52.06% | 194,000 -23.62% | 254,000 -66.22% | |
Cash from Investing Activities | 61.6M +398.64% | -20.6M +2,062.96% | -953,000 -189.91% | 1.1M -73.95% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 39.9M -79.49% | 194.6M +66.44% | 116.9M +20.38% | 97.1M +34.31% | |
Financials Ratio | |||||
Gross Margin | 88.66% -1.68% | 90.18% +1.68% | 88.68% +0.65% | 88.11% -1.30% | |
Operating Margin | -113.73% +6.23% | -107.06% +35.12% | -79.23% -35.49% | -122.82% -36.07% | |
Return on Assets | -63.14% +15.47% | -54.68% -16.05% | -65.14% -24.24% | -85.98% -6.22% | |
Return on Equity | 268.64% -21.64% | 342.83% +159.15% | 132.29% -51.23% | 271.24% +228.22% | |
Revenue Growth | 21.45% +130.86% | 9.29% -67.42% | 28.52% -16.01% | 33.96% -88.94% | |
Current Ratio | 4.01 -33.31% | 6.01 +10.87% | 5.42 +0.57% | 5.39 +5.45% | |
Cash Ratio | 2.39 -36.26% | 3.74 +22.97% | 3.04 +31.38% | 2.32 +16.89% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow